Entrada Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview

Entrada Therapeutics

03/11/2023 14:43

* Entrada Therapeutics Inc  TRDA.OQ   TRDA.O  is expected
to show
a rise in quarterly revenue when it reports  results 
    * The Boston Massachusetts-based  company is expected to
report
revenue of $9.598 million, according to the mean estimate from 4
analysts, based on LSEG data.  
    * ​Refinitiv's mean analyst estimate for Entrada
Therapeutics Inc
is for a loss of 74 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Entrada
Therapeutics Inc is $25​, above​ its last closing price
of $15.67. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.68       -0.69      -0.78     Missed  -13
 Mar. 31 2023  0.90        0.97       -0.21     Missed  -121.7
 Dec. 31 2022  -0.83       -0.83      -0.79     Beat    4.4​
 Sep. 30 2022  -0.75       -0.76      -0.80     Missed  -5.3
 ​​Jun.        -0.72       -0.72      -0.74     Missed  -2.2
 30 2022                                                
 Mar. 31 2022  -0.65       -0.65      -0.69     Missed  -5.3​
 Dec. 31 2021  -1.29       -1.28      -0.89     Beat    30.7
 Sep. 30 2021  -0.87       -0.87      -9.78     Missed  -1,024
                                                        .1
 This summary was machine generated November 3 at 14:43 GMT.  All
figures in US dollars  unless otherwise stated